Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an announcement.
Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program. As of December 16, 2025, the company has repurchased a total of 2,768,487 ordinary fully paid securities, with an additional 184,430 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, providing pathology services and clinical laboratory testing. The company focuses on delivering high-quality diagnostic services to healthcare professionals and patients across Australia.
Average Trading Volume: 789,003
Technical Sentiment Signal: Buy
Current Market Cap: A$546.7M
Learn more about ACL stock on TipRanks’ Stock Analysis page.